首页> 外文期刊>癌と化学療法 >Development of acute type, CD 8 positive adult T-cell leukemia in a carrier of hepatitis B virus--possible therapeutic effect of lamivudine combined with chemotherapy
【24h】

Development of acute type, CD 8 positive adult T-cell leukemia in a carrier of hepatitis B virus--possible therapeutic effect of lamivudine combined with chemotherapy

机译:急性型,CD 8阳性成人T细胞白血病在乙型肝炎病毒载体中的急性型成人T细胞白血病 - Lamivudine与化疗联合化疗的可能治疗效果

获取原文
获取原文并翻译 | 示例
           

摘要

Cases of adult T-cell leukemia (ATL) with aberrant phenotypes have a very poor prognosis. We report the development of acute type, CD 8 positive ATL in a carrier of hepatitis B virus (HBV). The patient was treated with a combination of lamivudine and chemotherapy and consequently had longer-term survival than those reported previously. A 64-year-old(corrected 65-year-old) man was referred to our hospital in January 2002 because of ascites and abdominal tumor. He was positive for anti-HTLV-1 antibody and HBV surface antigen. Generalized computed tomography demonstrated bilateral pleural effusion, abdominal mass, and massive ascites. Cytological examination of ascitis revealed numerous atypical lymphoid cells,which were positive for CD 2, CD 5, CD 8, and CD 25. Monoclonal integration of HTLV-1 provirus was detected by Southern blot analysis on DNA extracted from lymphoid cells. A diagnosis of acute type, CD 8 positive ATL was made. Lamivudine was administered for prevention of chemotherapy induced HBV reactivation. Subsequently, he was treated with 6 cycles of CHOP and went into remission. He maintained clinical remission during a follow-up of 13 months and then relapsed. Further salvage therapies were provided with a transient effect. He died of sepsis in February 2004. The overall survival time of this patient was 25 months. It is possible that lamivudine combined with chemotherapy may have had a therapeutic effect on ATL in this case.
机译:成人T细胞白血病(ATL)具有异常表型的预后具有非常差的预后。我们报告了乙型肝炎病毒(HBV)载体中急性型CD 8阳性ATL的发育。患者用拉米夫定和化学疗法的组合治疗,因此具有比以前所报道的那些更长的存活率。由于腹水和腹部肿瘤,一名64岁(纠正了65岁)的人被提交给我们的医院。他对抗HTLV-1抗体和HBV表面抗原呈阳性。广义计算断层扫描显示双侧胸腔积液,腹部肿块和大规模腹水。茜素炎的细胞学检查揭示了许多非典型淋巴细胞,这对于CD 2,Cd 5,CD 8和Cd 25呈阳性。通过淋巴细胞中提取的DNA的Southern印迹分析检测HTLV-1潜水员的单克隆整合。急性型急性型,CD 8阳性ATL进行了诊断。施用拉米夫定用于预防化疗诱导的HBV再活化。随后,他被6个循环的剁待遇,并进入缓解。他在13个月后保持临床缓解,然后复发。进一步挽救疗法具有瞬态效应。他于2004年2月去世了败血症。本患者的整体生存时间为25个月。在这种情况下,拉米夫定联合化学疗法可能对ATL进行治疗效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号